BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 19364050)

  • 1. Optimizing outcomes in HER2-positive breast cancer: the molecular rationale.
    Esteva FJ; Pusztai L
    Oncology (Williston Park); 2005 Nov; 19(13 Suppl 5):4. PubMed ID: 19364050
    [No Abstract]   [Full Text] [Related]  

  • 2. New research on the treatment of small HER2-positive breast cancers.
    Krop IE
    Clin Adv Hematol Oncol; 2014 Feb; 12(2):124-7. PubMed ID: 24892258
    [No Abstract]   [Full Text] [Related]  

  • 3. Implementation of trastuzumab in conjunction with adjuvant chemotherapy in the treatment of non-metastatic breast cancer in the Netherlands.
    de Munck L; Schaapveld M; Siesling S; Wesseling J; Voogd AC; Tjan-Heijnen VC; Otter R; Willemse PH
    Breast Cancer Res Treat; 2011 Aug; 129(1):229-33. PubMed ID: 21431871
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HER2 status and benefit from adjuvant trastuzumab in breast cancer.
    Paik S; Kim C; Wolmark N
    N Engl J Med; 2008 Mar; 358(13):1409-11. PubMed ID: 18367751
    [No Abstract]   [Full Text] [Related]  

  • 5. Next-generation targeted agents in HER2-positive metastatic breast cancer.
    Perez EA
    Clin Adv Hematol Oncol; 2012 Jul; 10(7):465-7. PubMed ID: 22895288
    [No Abstract]   [Full Text] [Related]  

  • 6. Adjuvant trastuzumab for HER2-positive early breast cancer.
    Palmieri FM; Myatt CV; Perez EA
    Clin J Oncol Nurs; 2010 Jun; 14(3):326-36. PubMed ID: 20529794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer stem cell hypothesis and trastuzumab in HER2-negative tumors.
    Tuma RS
    J Natl Cancer Inst; 2012 Jul; 104(13):968-9. PubMed ID: 22745473
    [No Abstract]   [Full Text] [Related]  

  • 8. Trastuzumab and beyond: New possibilities for the treatment of HER2-positive breast cancer.
    Morris SR; Carey LA
    Oncology (Williston Park); 2006 Dec; 20(14):1763-71; discussion 1771-2, 1774-6. PubMed ID: 17263127
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treating the HER2 pathway in early and advanced breast cancer.
    Pegram MD
    Hematol Oncol Clin North Am; 2013 Aug; 27(4):751-65, viii. PubMed ID: 23915743
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hormone receptor-positive early breast cancer: controversies in the use of adjuvant chemotherapy.
    Montemurro F; Aglietta M
    Endocr Relat Cancer; 2009 Dec; 16(4):1091-102. PubMed ID: 19726539
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patients with anti-HER2 responsive disease: definition and adjuvant therapies.
    Burstein HJ
    Breast; 2011 Oct; 20 Suppl 3():S132-4. PubMed ID: 22015280
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimizing chemotherapy-free survival for the ER/HER2-positive metastatic breast cancer patient.
    Glück S; Arteaga CL; Osborne CK
    Clin Cancer Res; 2011 Sep; 17(17):5559-61. PubMed ID: 21764887
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HER2-positive breast cancer: beyond trastuzumab.
    Murphy CG; Fornier M
    Oncology (Williston Park); 2010 Apr; 24(5):410-5. PubMed ID: 20480738
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Target therapy in elderly breast cancer patients.
    Carli P; Turchet E; Quitadamo D; Spada A; Miolo G; Lamaj E; Spazzapan S; Di Lauro V; Dolcetti R; Veronesi A; Crivellari D
    Crit Rev Oncol Hematol; 2012 Sep; 83(3):422-31. PubMed ID: 22257652
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current and future anti-HER2 therapy in breast cancer.
    Vrbic S; Pejcic I; Filipovic S; Kocic B; Vrbic M
    J BUON; 2013; 18(1):4-16. PubMed ID: 23613383
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improving treatment of HER2-positive cancers: opportunities and challenges.
    Stern HM
    Sci Transl Med; 2012 Mar; 4(127):127rv2. PubMed ID: 22461643
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Predictive value of Her2/neu expression/amplification for the targeted treatment of breast cancer].
    Lehr HA; Schaefer SC; Delaloye JF
    Rev Med Suisse; 2009 Jul; 5(211):1525-9. PubMed ID: 19694364
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of trastuzumab in the management of HER2-positive metastatic breast cancer: an updated review.
    Tokuda Y; Suzuki Y; Saito Y; Umemura S
    Breast Cancer; 2009; 16(4):295-300. PubMed ID: 19609647
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is trastuzumab active following conventional adjuvant chemotherapy in HER2-positive early breast cancer?
    Seidman AD
    Nat Clin Pract Oncol; 2006 Apr; 3(4):178-9. PubMed ID: 16596138
    [No Abstract]   [Full Text] [Related]  

  • 20. Trastuzumab in small tumours and in elderly women.
    Albanell J; Ciruelos EM; Lluch A; Muñoz M; Rodríguez CA
    Cancer Treat Rev; 2014 Feb; 40(1):41-7. PubMed ID: 23659993
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.